BACKGROUND: Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitemia and associated maternal anemia, premature delivery, and low birth weight. However, the optimal regimen in the setting of a high prevalence of human immunodeficiency virus (HIV) infection remains unclear. METHODS: In Malawi, where the efficacy of SP for the treatment of malaria in children is decreasing, we conducted a randomized, nonblinded study to compare the efficacy of monthly SP IPTp with a 2-dose regimen for the prevention of placental parasitemia in HIV-positive and -negative primigravid and secundigravid women. RESULTS: Of HIV-positive women, 7.8% who received monthly SP had placental malaria, compared with 21.5% of those who received 2-dose SP (relative risk [RR], 0.36 [95% confidence interval {CI}, 0.17-0.79]). Of HIV-negative women, 2.3% who received monthly SP and 6.3% who received 2-dose SP had placental malaria (RR, 0.37 [95% CI, 0.11-1.19]). Less than 1% of women reported adverse drug reactions, with no increase in HIV-positive women or those who received monthly SP. CONCLUSIONS: In HIV-positive pregnant women, monthly SP IPTp is more efficacious than a 2-dose regimen in preventing placental malaria. The study also demonstrates the continued efficacy of SP for the prevention of placental malaria, even in the face of its decreasing efficacy for the treatment of malaria in children. In areas with intense transmission of falciparum malaria and a high prevalence of HIV infection, monthly SP IPTp should be adopted.
RCT Entities:
BACKGROUND: Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) decreases placental malaria parasitemia and associated maternal anemia, premature delivery, and low birth weight. However, the optimal regimen in the setting of a high prevalence of human immunodeficiency virus (HIV) infection remains unclear. METHODS: In Malawi, where the efficacy of SP for the treatment of malaria in children is decreasing, we conducted a randomized, nonblinded study to compare the efficacy of monthly SP IPTp with a 2-dose regimen for the prevention of placental parasitemia in HIV-positive and -negative primigravid and secundigravid women. RESULTS: Of HIV-positive women, 7.8% who received monthly SP had placental malaria, compared with 21.5% of those who received 2-dose SP (relative risk [RR], 0.36 [95% confidence interval {CI}, 0.17-0.79]). Of HIV-negative women, 2.3% who received monthly SP and 6.3% who received 2-dose SP had placental malaria (RR, 0.37 [95% CI, 0.11-1.19]). Less than 1% of women reported adverse drug reactions, with no increase in HIV-positive women or those who received monthly SP. CONCLUSIONS: In HIV-positive pregnant women, monthly SP IPTp is more efficacious than a 2-dose regimen in preventing placental malaria. The study also demonstrates the continued efficacy of SP for the prevention of placental malaria, even in the face of its decreasing efficacy for the treatment of malaria in children. In areas with intense transmission of falciparum malaria and a high prevalence of HIV infection, monthly SP IPTp should be adopted.
Authors: Sara A Healy; Michal Fried; Thomas Richie; Karin Bok; Maggie Little; Allison August; Laura Riley; Geeta K Swamy; Blair J Wylie; Clara Menendez; Atis Muehlenbachs; Ogobara Doumbo; Brian Greenwood; Peter F Billingsley; Stephen L Hoffman; Patrick E Duffy Journal: Vaccine Date: 2019-01-06 Impact factor: 3.641
Authors: Steve M Taylor; Alejandro L Antonia; Ebbie Chaluluka; Victor Mwapasa; Gaoqian Feng; Malcolm E Molyneux; Feiko O ter Kuile; Steven R Meshnick; Stephen J Rogerson Journal: Clin Infect Dis Date: 2012-03-22 Impact factor: 9.079
Authors: Julie Gutman; Dyson Mwandama; Ryan E Wiegand; Doreen Ali; Don P Mathanga; Jacek Skarbinski Journal: J Infect Dis Date: 2013-06-24 Impact factor: 5.226
Authors: Moses R Kamya; Pauline Byakika-Kibwika; Anne F Gasasira; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan Journal: Future Virol Date: 2012 Impact factor: 1.831
Authors: Brian M Greenwood; David A Fidock; Dennis E Kyle; Stefan H I Kappe; Pedro L Alonso; Frank H Collins; Patrick E Duffy Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Godfrey Martin Mubyazi; Pascal Magnussen; Catherine Goodman; Ib Christian Bygbjerg; Andrew Yona Kitua; Oystein Evjen Olsen; Jens Byskov; Kristian Schultz Hansen; Paul Bloch Journal: Open Trop Med J Date: 2008
Authors: Patrick M Newman; Humphrey Wanzira; Gabriel Tumwine; Emmanuel Arinaitwe; Sarah Waldman; Jane Achan; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Tamara D Clark; Deborah Cohan Journal: Malar J Date: 2009-11-14 Impact factor: 2.979